keyword
MENU ▼
Read by QxMD icon Read
search

Neuro-oncology

keyword
https://www.readbyqxmd.com/read/29352231/the-direction-of-tumour-growth-in-glioblastoma-patients
#1
Morteza Esmaeili, Anne Line Stensjøen, Erik Magnus Berntsen, Ole Solheim, Ingerid Reinertsen
Generating MR-derived growth pattern models for glioblastoma multiforme (GBM) has been an attractive approach in neuro-oncology, suggesting a distinct pattern of lesion spread with a tendency in growing along the white matter (WM) fibre direction for the invasive component. However, the direction of growth is not much studied in vivo. In this study, we sought to study the dominant directions of tumour expansion/shrinkage pre-treatment. We examined fifty-six GBMs at two time-points: at radiological diagnosis and as part of the pre-operative planning, both with contrast-enhanced T1-weighted MRIs...
January 19, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29340286/cancer-imaging-phenomics-toolkit-quantitative-imaging-analytics-for-precision-diagnostics-and-predictive-modeling-of-clinical-outcome
#2
Christos Davatzikos, Saima Rathore, Spyridon Bakas, Sarthak Pati, Mark Bergman, Ratheesh Kalarot, Patmaa Sridharan, Aimilia Gastounioti, Nariman Jahani, Eric Cohen, Hamed Akbari, Birkan Tunc, Jimit Doshi, Drew Parker, Michael Hsieh, Aristeidis Sotiras, Hongming Li, Yangming Ou, Robert K Doot, Michel Bilello, Yong Fan, Russell T Shinohara, Paul Yushkevich, Ragini Verma, Despina Kontos
The growth of multiparametric imaging protocols has paved the way for quantitative imaging phenotypes that predict treatment response and clinical outcome, reflect underlying cancer molecular characteristics and spatiotemporal heterogeneity, and can guide personalized treatment planning. This growth has underlined the need for efficient quantitative analytics to derive high-dimensional imaging signatures of diagnostic and predictive value in this emerging era of integrated precision diagnostics. This paper presents cancer imaging phenomics toolkit (CaPTk), a new and dynamically growing software platform for analysis of radiographic images of cancer, currently focusing on brain, breast, and lung cancer...
January 2018: Journal of Medical Imaging
https://www.readbyqxmd.com/read/29337169/the-prognostic-role-of-gender-and-mgmt-methylation-status-in-glioblastoma-patients-the-female-power
#3
Enrico Franceschi, Alicia Tosoni, Santino Minichillo, Roberta Depenni, Alexandro Paccapelo, Stefania Bartolini, Maria Michiara, Giacomo Pavesi, Benedetta Urbini, Girolamo Crisi, Michele A Cavallo, Luigino Tosatto, Claudio Dazzi, Claudia Biasini, Giuseppe Pasini, Damiano Balestrini, Francesca Zanelli, Vania Ramponi, Antonio Fioravanti, Ermanno Giombelli, Dario De Biase, Agostino Baruzzi, Alba A Brandes
BACKGROUND: Clinical and molecular factors are essential to define prognosis in glioblastoma (GBM) patients. MGMT methylation status, age, Karnofsky performance status (KPS) and extent of surgical resection are the most relevant prognostic factors. The role of gender in predicting patients prognosis has been investigated showing a slight survival advantage for female patients. METHODS: We performed a prospective evaluation from a registry called the Project of Emilia Romagna on Neuro-Oncology (PERNO) about prognostic factors in GBM patients who received standard treatment...
January 11, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29333521/nanomaterials-for-convection-enhanced-delivery-of-agents-to-treat-brain-tumors
#4
Young-Eun Seo, Tom Bu, W Mark Saltzman
Nanomaterials represent a promising and versatile platform for the delivery of therapeutics to the brain. Treatment of brain tumors has been a long-standing challenge in the field of neuro-oncology. The current standard of care - a multimodal approach of surgery, radiation and chemotherapy - yields only a modest therapeutic benefit for patients with malignant gliomas. A major obstacle for treatment is the failure to achieve sufficient delivery of therapeutics at the tumor site. Recent advances in local drug delivery techniques, along with the development of highly effective brain-penetrating nanocarriers, have significantly improved treatment and imaging of brain tumors in preclinical studies...
December 2017: Current Opinion in Biomedical Engineering
https://www.readbyqxmd.com/read/29332604/the-effect-of-an-adenosine-a2a-agonist-on-intra-tumoral-concentrations-of-temozolomide-in-patients-with-recurrent-glioblastoma
#5
Sadhana Jackson, Jon Weingart, Edjah K Nduom, Thura T Harfi, Richard T George, Dorothea McAreavey, Xiaobu Ye, Nicole M Anders, Cody Peer, William D Figg, Mark Gilbert, Michelle A Rudek, Stuart A Grossman
BACKGROUND: The blood-brain barrier (BBB) severely limits the entry of systemically administered drugs including chemotherapy to the brain. In rodents, regadenoson activation of adenosine A2A receptors causes transient BBB disruption and increased drug concentrations in normal brain. This study was conducted to evaluate if activation of A2A receptors would increase intra-tumoral temozolomide concentrations in patients with glioblastoma. METHODS: Patients scheduled for a clinically indicated surgery for recurrent glioblastoma were eligible...
January 15, 2018: Fluids and Barriers of the CNS
https://www.readbyqxmd.com/read/29329454/a-change-at-the-helm-of-neuro-oncology
#6
Kenneth Aldape
No abstract text is available yet for this article.
January 10, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29329453/response-to-harreld-re-response-assessment-in-medulloblastoma-and-leptomeningeal-seeding-tumors-recommendations-from-the-response-assessment-in-pediatric-neuro-oncology-committee
#7
Katherine E Warren, Gilbert Vezina, Tina Y Poussaint, Monika Warmuth-Metz, Roger J Packer, Mark W Kieran
No abstract text is available yet for this article.
January 10, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29329452/comment-on-response-assessment-in-medulloblastoma-and-leptomeningeal-seeding-tumors-recommendations-from-the-response-assessment-in-pediatric-neuro-oncology-committee
#8
https://www.readbyqxmd.com/read/29304919/cranial-tumor-surgical-outcomes-at-a-high-volume-academic-referral-center
#9
Desmond A Brown, Benjamin T Himes, Brittny T Major, Benjamin F Mundell, Ravi Kumar, Bruce Kall, Fredric B Meyer, Michael J Link, Bruce E Pollock, John D Atkinson, Jamie J Van Gompel, W Richard Marsh, Giuseppe Lanzino, Mohamad Bydon, Ian F Parney
OBJECTIVE: To determine adverse event rates for adult cranial neuro-oncologic surgeries performed at a high-volume quaternary academic center and assess the impact of resident participation on perioperative complication rates. PATIENTS AND METHODS: All adult patients undergoing neurosurgical intervention for an intracranial neoplastic lesion between January 1, 2009, and December 31, 2013, were included. Cases were categorized as biopsy, extra-axial/skull base, intra-axial, or transsphenoidal...
January 2018: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/29304360/clinical-trial-design-for-local-therapies-for-brain-metastases-a-guideline-by-the-response-assessment-in-neuro-oncology-brain-metastases-working-group
#10
REVIEW
Brian M Alexander, Paul D Brown, Manmeet S Ahluwalia, Hidefumi Aoyama, Brigitta G Baumert, Susan M Chang, Laurie E Gaspar, Steven N Kalkanis, David R Macdonald, Minesh P Mehta, Riccardo Soffietti, John H Suh, Martin J van den Bent, Michael A Vogelbaum, Jeffrey S Wefel, Eudocia Q Lee, Patrick Y Wen
The goals of therapeutic and biomarker development form the foundation of clinical trial design, and change considerably from early-phase to late-phase trials. From these goals, decisions on specific clinical trial design elements, such as endpoint selection and statistical approaches, are formed. Whereas early-phase trials might focus on finding a therapeutic signal to make decisions on further development, late-phase trials focus on the confirmation of therapeutic impact by considering clinically meaningful endpoints...
January 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29304358/clinical-trial-design-for-systemic-agents-in-patients-with-brain-metastases-from-solid-tumours-a-guideline-by-the-response-assessment-in-neuro-oncology-brain-metastases-working-group
#11
REVIEW
D Ross Camidge, Eudocia Q Lee, Nancy U Lin, Kim Margolin, Manmeet S Ahluwalia, Martin Bendszus, Susan M Chang, Janet Dancey, Elisabeth G E de Vries, Gordon J Harris, F Stephen Hodi, Andrew B Lassman, David R Macdonald, David M Peereboom, David Schiff, Ricardo Soffietti, Martin J van den Bent, Jeffrey S Wefel, Patrick Y Wen
Patients with active CNS disease are often excluded from clinical trials, and data regarding the CNS efficacy of systemic agents are usually obtained late in the drug development process or not at all. In this guideline from the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group, we provide detailed recommendations on when patients with brain metastases from solid tumours should be included or excluded in clinical trials of systemic agents. We also discuss the limitations of retrospective studies in determining the CNS efficacy of systemic drugs...
January 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29295569/extent-of-resection-in-newly-diagnosed-glioblastoma-impact-of-a-specialized-neuro-oncology-care-center
#12
Amer Haj, Christian Doenitz, Karl-Michael Schebesch, Denise Ehrensberger, Peter Hau, Kurt Putnik, Markus J Riemenschneider, Christina Wendl, Michael Gerken, Tobias Pukrop, Alexander Brawanski, Martin A Proescholdt
Treatment of glioblastoma (GBM) consists of microsurgical resection followed by concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of a specialized neuro-oncology care center (NOC) has enabled the implementation of a large technical portfolio including functional imaging, awake craniotomy, PET scanning, fluorescence-guided resection, and integrated postsurgical therapy. This study analyzed whether the technically improved neurosurgical treatment structure yields a higher rate of complete resection, thus ultimately improving patient outcome...
December 25, 2017: Brain Sciences
https://www.readbyqxmd.com/read/29282517/11c-met-pet-mri-for-detection-of-recurrent-glioma
#13
C Deuschl, J Kirchner, T D Poeppel, B Schaarschmidt, S Kebir, N El Hindy, J Hense, H H Quick, M Glas, K Herrmann, L Umutlu, C Moenninghoff, A Radbruch, M Forsting, M Schlamann
INTRODUCTION: Radiological assessment of brain tumors is widely based on the Radiology Assessment of Neuro-Oncology (RANO) criteria that consider non-specific T1 and T2 weighted images. Limitation of the RANO criteria is that they do not include metabolic imaging techniques that have been reported to be helpful to differentiate treatment related changes from true tumor progression. In the current study, we assessed if the combined use of MRI and PET with hybrid 11C-MET PET/MRI can improve diagnostic accuracy and diagnostic confidence of the readers to differentiate treatment related changes from true progression in recurrent glioma...
December 28, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29275519/investigation-of-the-usefulness-of-fluorescein-sodium-fluorescence-in-stereotactic-brain-biopsy
#14
Ady Thien, Julian Xinguang Han, Krishan Kumar, Yew Poh Ng, Jai Prashanth Rao, Wai Hoe Ng, Nicolas Kon Kam King
BACKGROUND: Intraoperative frozen section assessment, to confirm acquisition of pathological tissues, is used in stereotactic brain biopsy to minimise sampling errors. Limitations include the dependence on dedicated neuro-oncology pathologists and an increase in operative duration. We investigated the use of intraoperative fluorescein sodium, and compared it to frozen section assessment, for confirming pathological tissue samples in the stereotactic biopsy of gadolinium-contrast-enhancing brain lesions...
December 23, 2017: Acta Neurochirurgica
https://www.readbyqxmd.com/read/29241169/imaging-of-intracranial-gliomas
#15
Yuko Ono, Mikhail F Chernov, Yoshihiro Muragaki, Takashi Maruyama, Kayoko Abe, Hiroshi Iseki
Combined use of contemporary radiological modalities, particularly integration of structural, metabolic, and functional imaging, provides optimal multifaceted information for detailed characterization of intracranial gliomas. It allows differentiation of the tumor from non-neoplastic pathology, its non-invasive histopathological typing and grading, prediction of patient prognosis and clinical course of the disease, detailed planning of surgical resection or biopsy, critical postoperative assessment of the residual lesion, effective surveillance during follow-up with evaluation of effectiveness of the adjuvant therapy and timely identification of recurrence, and even insights into molecular signatures of the neoplasms...
2018: Progress in Neurological Surgery
https://www.readbyqxmd.com/read/29236238/internet-based-guided-self-help-for-glioma-patients-with-depressive-symptoms-a-randomized-controlled-trial
#16
Florien W Boele, Martin Klein, Irma M Verdonck-de Leeuw, Pim Cuijpers, Jan J Heimans, Tom J Snijders, Maaike Vos, Ingeborg Bosma, Cees C Tijssen, Jaap C Reijneveld
Depressive symptoms are common in glioma patients, and can negatively affect health-related quality of life (HRQOL). We performed a nation-wide randomized controlled trial to evaluate the effects of an online guided self-help intervention for depressive symptoms in adult glioma patients. Glioma patients with depressive symptoms were randomized to a 5-week online course based on problem-solving therapy, or a waiting list control group. After having received the intervention, the glioma patient groups combined were compared with patients with cancer outside the central nervous system (non-CNS cancer controls), who also received the intervention...
December 13, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29235051/development-of-the-cns-tap-tool-for-the-selection-of-precision-medicine-therapies-in-neuro-oncology
#17
Joseph R Linzey, Bernard L Marini, Amy Pasternak, Cory Smith, Zac Miklja, Lili Zhao, Chandan Kumar-Sinha, Alyssa Paul, Nicholas Harris, Patricia L Robertson, Lindsey M Hoffman, Arul Chinnaiyan, Rajen Mody, Carl Koschmann
The number of targeted therapies utilized in precision medicine are rapidly increasing. Neuro-oncology offers a unique challenge due to the varying blood brain barrier (BBB) penetration of each agent. Neuro-oncologists face a difficult task weighing the growing number of potential targeted therapies and their likelihood of BBB penetration. We developed the CNS TAP Working Group and performed an extensive literature review for the evidence-based creation of the CNS TAP tool, which was retrospectively validated by analyzing brain tumor patients who underwent therapy targeted based on genomic results from an academic sequencing study (MiOncoseq, n = 17) or private molecular profiling (Foundation One, n = 7)...
December 12, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29200118/palliative-care-end-of-life-care-and-advance-care-planning-in-neuro-oncology
#18
Tobias Walbert
PURPOSE OF REVIEW: Despite new therapeutic approaches, most patients with high-grade glioma face limited overall survival and have a high symptom burden throughout their disease trajectory, especially in the end-of-life phase. This article provides an overview of the role of palliative care in neuro-oncology. Management recommendations are made for neurologic symptoms in patients with advanced brain tumors, including headaches, nausea, and fatigue. Special attention is given to how and when to involve subspecialty palliative care and hospice services to improve symptom management during active tumor treatment and in the end-of-life phase of patients with brain tumors...
December 2017: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/29200114/neuroradiologic-pearls-for-neuro-oncology
#19
Joshua P Klein, Jorg Dietrich
PURPOSE OF REVIEW: This article reviews key principles in the identification of tumors of the central nervous system (CNS) using standard and advanced imaging modalities. This article highlights the pitfalls and pearls of the imaging evaluation of patients with cancer at time of diagnosis and during cancer therapy and discusses the challenges of the imaging evaluation of treatment-related toxicities. RECENT FINDINGS: Treatment of CNS tumors with surgery, chemotherapy, or radiation alters the imaging appearance of the tumor and can be associated with a variety of treatment-related toxicities...
December 2017: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/29196252/atypical-and-malignant-meningiomas-neuro-oncological-management-in-a-brazilian-cohort
#20
Benedito Jamilson Araújo Pereira, Antônio Nogueira de Almeida, Paulo Henrique Pires de Aguiar, Wellingson Silva Paiva, Hector Navarro Cabrera, Clemar Corrêa da Silva, Manoel Jacobsen Teixeira, Suely Kazue Nagahashi Marie
OBJECTIVE: To analyze grade II and III meningioma patients´ surgical and oncological managements in a follow-up of 15 years to get an overview of these patients outcome in a Brazilian cohort. METHODS: Cross-sectional study of 43 patients (26 females/ 17 males, age range from 20 to 83 years old, average 57.72±14.54) operated from 2000 to 2014 in a single institution, with the neuropathological diagnosis of meningioma grades II (39 cases) and III (4 cases) RESULTS: Radiotherapy: Twenty-four patients (55...
November 28, 2017: World Neurosurgery
keyword
keyword
1438
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"